What Should I Choose? (Moderated Digital Poster Session) Sunday, November 17, 2024, 3:45 p.m. (CST), 4:45 p.m. (EST) Presenting Author: Dion Zappe About AMVUTTRA ® (vutrisiran) AMVUTTRA ...

Continued growth momentum in total TTR, achieving global net product revenues for ONPATTRO and AMVUTTRA for the third quarter of $50 million and $259 million, respectively, which combined ...

Alnylam Pharmaceuticals ALNY announced that the FDA has accepted its supplemental new drug application (sNDA) seeking the ...

Alnylam's Amvuttra followed these results with a once per quarter subcutaneous injection, which can be administered at home, with reductions of 28% and 33% for overall mortality and cardiovascular ...

Alnylam's gene-silencing drug Amvuttra has been recommended as a treatment for hereditary transthyretin-related (ATTR) amyloidosis by NICE, paving the way for the drug to be made available on the ...

Strong patient uptake of next-generation drug Amvuttra (for ATTR amyloidosis with polyneuropathy) is driving sales, accounting for $259 million of the quarter’s net product revenue, representing ...

Wolfe Research downgraded Alnylam (ALNY) to Underperform from Peer Perform with a $205 price target The firm cites expectations that the company will expand its approved Amvuttra into the much ...

Analyst Andy Chen said that while sales of Amvuttra (vutrisiran) will be the primary driver of Alnylam's stock price, new ...

AMVUTTRA, whose generic name is Vutrisiran, received FDA approval in June 2022 for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults.